B. Braun SE

What B. Braun SE does

B. Braun SE is a privately held German medical technology and pharmaceutical company headquartered in Melsungen, founded in 1839 and structured as a Societas Europaea under family ownership with Anna Maria Braun as Chair of the Management Board. The company manufactures and sells medical devices, sterile pharmaceutical products, and integrated care solutions spanning more than 15 therapy areas including infusion therapy, surgical instruments and visualization, clinical nutrition, extracorporeal blood treatment (dialysis), interventional vascular therapy, minimally invasive and robotic surgery, wound management, orthopedic joint replacement, pain therapy, continence care and urology, neurosurgery, spinal surgery, and hygiene management. Notable proprietary products include the Spaceplus automated infusion system with the OnlineSuite digital medication management platform, the AESCULAP EinsteinVision 3.0 FI 3D fluorescence imaging system, and a coin-sized implantable intracranial pressure sensor approved by Australia's TGA for hydrocephalus management. The company operates through wholly-owned subsidiaries including B. Braun Melsungen AG (infusion and IV equipment), Aesculap (surgical instruments), B. Braun Renal Care (dialysis centers), and the rebranded B. Braun Pharma & MedTech Partner (OEM and contract development services), serving customers across more than 40 countries with a direct enterprise sales motion and regional subsidiaries.

The business model combines hardware sales of medical devices and pharmaceutical products with recurring revenue from HomeCare and dialysis services, professional services revenue from the Aesculap Academy training platform and Pharma & MedTech Partner contract development, and OEM/contract manufacturing. Pricing is quote-based and not publicly disclosed, with sales executed primarily through a direct field sales force targeting hospitals, outpatient surgery centers, clinics, and home healthcare patients. Revenue reached €9.4 billion in FY2025 with currency-adjusted growth of 5.1%, distributed across a diversified portfolio that competes with BD, Baxter, ICU Medical, Fresenius Kabi, Boston Scientific, and others across multiple medtech segments. The company maintains global manufacturing and regulatory infrastructure (EU MDR, FDA, Australian TGA) and pursues inorganic growth through targeted acquisitions such as True Digital Surgery (September 2025) while divesting non-core assets such as the endoscopic vacuum therapy line sold to Boston Scientific in March 2024.

Name

B. Braun SE

Legal name

B. Braun SE

Website

https://bbraun.de

Company type

Private

Founded year

1839

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

B. Braun SE is a privately held German medical technology and pharmaceutical company that manufactures infusion therapy systems, surgical instruments, dialysis products, and clinical nutrition solutions for hospitals and home healthcare patients across more than 40 countries. Revenue reached €9.4 billion in FY2025.

Ownership category

akta.pro rank

Product category

Medical Devices and Pharmaceutical Products

NAICS

Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113), Pharmaceutical Preparation Manufacturing (325412), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Medical Equipment and Supplies Manufacturing (3391)

SIC

Surgical & Medical Instruments & Apparatus (3841), Pharmaceutical Preparations (2834), Electromedical & Electrotherapeutic Apparatus (3845), Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047)

akta.pro primary industry

Surgical Stapling, Suturing & Hemostasis (Staplers, Clips, Sealants, Tourniquets) (HLAHADAL)

akta.pro secondary industries

Pain Management & Anesthesiology Pharmaceuticals (HLAIAAAN), Personal Medical Devices & Home Diagnostics (Thermometers, Blood Pressure Monitors, Glucose Meters, Rapid Tests) (CRADAMAK)

Keywords

• Medical device manufacturing
• Infusion therapy systems
• Surgical instruments
• Clinical nutrition products
• Dialysis equipment

Headquarters

HQ city

Melsungen

HQ country

Germany

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Medical Devices and Equipment Sales: Sale of medical devices including infusion systems, surgical instruments, catheters, dialysis equipment, and other medical technology products to healthcare facilities globally
2. Pharmaceutical Products: Pharmaceutical products including clinical nutrition, infusion solutions, and medication delivery systems
3. OEM/Contract Manufacturing Services: Rebranded as B. Braun Pharma & MedTech Partner, providing early-stage development support, regulatory navigation, manufacturing, packaging, and lifecycle management services for pharmaceutical and medtech customers
4. HomeCare Services: Coordinating medical care for patients discharged from hospital, including dialysis services, infusion therapy, and chronic disease management at home
5. Aesculap Academy Training: Medical education and training services for healthcare professionals

Go-to-market motion1 record

Distribution channels5 records

Marketing channels7 records

Core offering

B. Braun SE manufactures and sells medical devices, surgical instruments, and pharmaceutical products across more than 15 therapy areas including infusion therapy, surgical instruments, clinical nutrition, extracorporeal blood treatment (dialysis), hygiene management, interventional vascular therapy, minimally invasive surgery, wound management, orthopedic joint replacement, pain therapy, continence care and urology, neurosurgery, and spinal surgery. The company complements its product portfolio with HomeCare services, Aesculap Academy medical training, and the rebranded Pharma & MedTech Partner contract manufacturing business for pharmaceutical and medtech companies.

Product overview

B. Braun SE is a global medical technology company offering a comprehensive portfolio of healthcare products and solutions organized around integrated care pathways. The company's offerings span infusion therapy (Spaceplus automated infusion systems with OnlineSuite digital management), surgical solutions (Aesculap instruments, EinsteinVision 3D fluorescence imaging, robotic surgery), clinical nutrition therapy, extracorporeal blood treatment (dialysis), continence care and urology, wound management, and hospital IT integration. B. Braun positions itself as a full-solution provider through its Aesculap Academy training services, HomeCare patient services, and its rebranded Pharma & MedTech Partner OEM division, enabling the company to serve healthcare facilities from consumables to capital equipment across the entire care continuum.

Differentiator

Problem solved

Functional benefit

Brands

• AESCULAP EinsteinVision 3.0 FI: 3D fluorescence imaging system for surgical visualization
• Spaceplus
• Agile OP-Versorgung
• Aesculap Academy
• B. Braun HomeCare
• B. Braun OEM Division
• My B. Braun

Products and services

• Spaceplus Automated Infusion System

Quantifiable outcome

• Revenue of €9.4 billion in FY 2025 with 5.1% currency-adjusted growth
• +2 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

Feature5 records

Partnerships

Seven partnerships are on record, tiered minor and core.

• Butterfly NetworkminorGTM or Marketing Partner · 18 May 2026Caroll H. Neubauer, former Chairman and CEO of B. Braun USA with 29 years of B. Braun experience (grew revenue from $1B to $8B+), appointed to Butterfly Network's Board of Directors. Brings healthcare executive expertise to Butterfly's semiconductor-based ultrasound platform, cloud software, and AI offerings.
• Royal Philips N.V.coreTechnology or Integration · 31 March 2026Philips collaborates with B. Braun to integrate their ventilators, anesthesia machines, and infusion pumps into Philips' patient monitoring ecosystem using Service-oriented Device Connectivity (SDC) standards. Part of Philips' Open operating room concept to consolidate patient monitoring and streamline clinical workflows from OR to ICU.
• Bookdialysis.comcoreStrategic or Co-development Partner · 26 February 2026Strategic collaboration under which B. Braun's dialysis centers join the curated global bookdialysis network. Partnership aims to expand access to safe, high-quality, and reliable renal care for chronic kidney disease patients who wish to travel, combining B. Braun's clinical standards with bookdialysis's travel coordination expertise.
• GIZ (Deutsche Gesellschaft für Internationale Zusammenarbeit)minorStrategic or Co-development Partner · 26 February 2026B. Braun joined GIZ and other medical technology companies (Delft Imaging, Drager, Sysmex Europe, Area9 Lyceum) to retrofit biomedical engineering laboratories at Kwame Nkrumah University of Science and Technology and University of Ghana. Project funded through develoPPP programme to provide industry-ready training for biomedical engineering students.
• True Digital SurgerycoreStrategic or Co-development Partner · 1 September 2025B. Braun acquired True Digital Surgery in September 2025 to enhance its digital surgery technology capabilities. This strategic acquisition strengthens B. Braun's position in surgical visualization and navigation technologies.
• Royal Philips N.V.coreTechnology or Integration · 1 July 2025Philips collaborated with B. Braun Melsungen AG alongside Dräger, Hamilton Medical, Getinge, and Lowenstein to introduce an open patient monitoring ecosystem designed for vendor-neutral device connectivity in July 2025.
• Boston Scientific CorporationminorStrategic or Co-development Partner · 1 March 2024Boston Scientific acquired endoscopic vacuum therapy assets from B. Braun Group in March 2024 to strengthen its portfolio in minimally invasive treatments. B. Braun divested this asset category to Boston Scientific.

Scale indicators10 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• Medtronic plc: Medtronic is a diversified medical device leader with overlapping portfolios in surgical instruments, neurosurgery, infusion pumps, and patient monitoring. Both companies serve the same hospital systems across multiple therapy areas.
• Stryker Corporation: Stryker is a broader medical device incumbent with overlapping exposure to surgical instruments, orthopedic joint replacement, and operating room equipment. While Stryker is more focused on orthopedics, both companies compete in surgical and orthopedic procedure markets.
• Boston Scientific Corporation: Boston Scientific acquired endoscopic vacuum therapy assets from B. Braun in March 2024 and competes in interventional vascular therapy and minimally invasive surgery. The recent acquisition illustrates Boston Scientific's strategy of acquiring B. Braun-adjacent assets.
• Johnson & Johnson (MedTech / Ethicon): Johnson & Johnson's MedTech division (Ethicon, DePuy Synthes) competes with B. Braun in surgical instruments, suturing, wound management, and orthopedic joint replacement. J&J is a much larger diversified medtech incumbent.
• Smith+Nephew: Smith+Nephew is a diversified medtech player with overlapping exposure to wound management, orthopedics, and sports medicine, competing with B. Braun in advanced wound care and orthopedic joint replacement.

Direct peers

• Baxter International: Baxter is a direct competitor across IV infusion therapy, IV solutions, pumps, and surgical products. Both companies sell infusion sets, catheters, and clinical nutrition products into overlapping hospital customers.
• Fresenius SE & Co. KGaA: Fresenius Kabi, a Fresenius SE subsidiary, is a direct competitor in IV infusion therapy, clinical nutrition, and IV fluids. Fresenius also operates Fresenius Medical Care for dialysis services, making it B. Braun's closest multi-vertical competitor in infusion and renal care.
• Becton, Dickinson and Company (BD): BD is a direct competitor in IV equipment, infusion therapy, and medication delivery systems. Both companies are identified as major players in IV equipment alongside ICU Medical in the same market.
• ICU Medical: ICU Medical competes directly with B. Braun in IV infusion equipment and Y-shaped infusion line connectors. Both serve the same hospital customer base with comparable infusion therapy product portfolios.

Emerging players

• ConvaTec Group: ConvaTec focuses on wound management, continence care, ostomy care, and infusion sets, partially overlapping with B. Braun's wound management, continence care/urology, and infusion therapy categories.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about B. Braun SE